Education
About Us
Working with TipRanks
Follow Us
CV Sciences (CVSI)
:CVSI
CVSI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.06
Previous CloseN/A
Volume110.38K
Average Volume (3M)271.26K
Market Cap
$6.97M
Enterprise Value$5.39M
Total Cash (Recent Filing)$812.00K
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding184,263,660
10 Day Avg. Volume376,100
30 Day Avg. Volume271,258
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-5.76
Price to Sales (P/S)0.00
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda-0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CV Sciences News
PremiumCompany Announcements
CV Sciences Holds 2025 Virtual Annual Meeting
PremiumCompany Announcements
CV Sciences Earnings Call: Balancing Challenges and Opportunities
PremiumCompany Announcements
CV Sciences Reports Q1 2025 Financial Results
PremiumCompany Announcements
CV Sciences Reports 2024 Financial Results and Strategic Growth
PremiumCompany Announcements
CV Sciences Navigates Challenges with Strategic Growth Initiatives
PremiumCompany Announcements
CV Sciences Reports 2024 Financial Results and Growth Plans
Options Prices
Currently, No data available
---
Ownership Overview
0.02%
Insiders
<0.01% Other Institutional Investors
99.98% Public Companies and
Individual Investors
CVSI FAQ
What was CV Sciences’s price range in the past 12 months?
CV Sciences lowest stock price was $0.02 and its highest was $0.06 in the past 12 months.
What is CV Sciences’s market cap?
CV Sciences’s market cap is $6.97M.
When is CV Sciences’s upcoming earnings report date?
CV Sciences’s upcoming earnings report date is Aug 18, 2025 which is in 44 days.
How were CV Sciences’s earnings last quarter?
CV Sciences released its earnings results on May 09, 2025. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is CV Sciences overvalued?
According to Wall Street analysts CV Sciences’s price is currently Overvalued.
Does CV Sciences pay dividends?
CV Sciences does not currently pay dividends.
What is CV Sciences’s EPS estimate?
CV Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences have?
CV Sciences has 184,263,660 shares outstanding.
What happened to CV Sciences’s price movement after its last earnings report?
CV Sciences reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of CV Sciences?
Currently, no hedge funds are holding shares in CVSI
Company Description
CV Sciences
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
CVSI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong efforts in maintaining a healthy gross margin, progress in market share and product innovation, and advancements in M&A strategies. However, these positives were tempered by a decline in revenues, manufacturing challenges, and regulatory impacts. Despite the revenue decline, the company's strategic initiatives and improved cost efficiencies present an optimistic outlook.Read More>